High Adiponectin Concentrations Are Associated with the Metabolically Healthy Obese Phenotype

Aguilar-Salinas, Carlos A.; García, Eduardo García; Robles, Lorena; Riaño, Daniela; Ruiz-Gómez, Doris Georgina; García-Ulloa, Ana Cristina; Melgarejo, Marco A.; Zamora, Margarita; Guillén-Pineda, Luz Elizabeth; Mehta, Roopa; Canizales‐Quinteros, Samuel; Luna, Ma Teresa Tusie; Gómez-Pérez, Francisco J.

doi:10.1210/jc.2007-2724

Cited by 263 publications

(235 citation statements)

References 20 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…The diagnosis of MHO was obtained based on the joint combination of each obesity marker (BMI, waist circumference and body fat percentage) and six different sets of cardiometabolic abnormalities (Karelis et al, 2004;Meigs et al, 2006;Aguilar-Salinas et al, 2008;Wildman et al, 2008;Lynch et al, 2009) (Table 1). There were no exclusion criteria such as menopause, hormonal use and medications affecting metabolism, as well as diabetes and CVDs; participants were selected if they presented with overweight or obesity using the different anthropometric markers (BMI, waist or body fat).…”

Section: Determination Of the Prevalence Of Metabolically Healthy Obesementioning

confidence: 99%

See 1 more Smart Citation

Metabolically healthy obesity: different prevalences using different criteria

Velho

Paccaud

Waeber³

et al. 2010

Eur J Clin Nutr

218

185

View full text Add to dashboard Cite

Objective: To estimate the prevalence of metabolically healthy obesity (MHO) according to different definitions. Methods: Population-based sample of 2803 women and 2557 men participated in the study. Metabolic abnormalities were defined using six sets of criteria, which included different combinations of the following: waist; blood pressure; total, high-density lipoprotein or low-density lipoprotein-cholesterol; triglycerides; fasting glucose; homeostasis model assessment; high-sensitivity C-reactive protein; personal history of cardiovascular, respiratory or metabolic diseases. For each set, prevalence of MHO was assessed for body mass index (BMI); waist or percent body fat. Results: Among obese (BMI X30 kg/m 2 ) participants, prevalence of MHO ranged between 3.3 and 32.1% in men and between 11.4 and 43.3% in women according to the criteria used. Using abdominal obesity, prevalence of MHO ranged between 5.7 and 36.7% (men) and 12.2 and 57.5% (women). Using percent body fat led to a prevalence of MHO ranging between 6.4 and 43.1% (men) and 12.0 and 55.5% (women). MHO participants had a lower odd of presenting a family history of type 2 diabetes. After multivariate adjustment, the odds of presenting with MHO decreased with increasing age, whereas no relationship was found with gender, alcohol consumption or tobacco smoking using most sets of criteria. Physical activity was positively related, whereas increased waist was negatively related with BMI-defined MHO. Conclusion: MHO prevalence varies considerably according to the criteria used, underscoring the need for a standard definition of this metabolic entity. Physical activity increases the likelihood of presenting with MHO, and MHO is associated with a lower prevalence of family history of type 2 diabetes.

show abstract

Section: Determination Of the Prevalence Of Metabolically Healthy Obesementioning

confidence: 99%

“…There are currently no unique criteria for MHO, and several definitions have been proposed (Meigs et al, 2006;Aguilar-Salinas et al, 2008;Karelis, 2008;Wildman et al, 2008;Lynch et al, 2009). The criteria used to define MHO are summarized in Table 1.…”

Section: Introductionmentioning

confidence: 99%

Metabolically healthy obesity: different prevalences using different criteria

Velho

Paccaud

Waeber³

et al. 2010

Eur J Clin Nutr

218

185

View full text Add to dashboard Cite

show abstract

“…[7][8][9] However, clinical experience and well-documented studies in different populations indicate that metabolically benign, insulin-sensitive phenotypes are not infrequent within the obesity spectrum. 10,11 Adiponectin is the most abundant adipokine in the circulation and has insulin-sensitizing, anti-inflammatory and atheroprotective properties. 12 Associations of low plasma adiponectin levels with IR, components of the metabolic syndrome, the incidence of type 2 diabetes and increased cardiovascular risk, independent of established risk factors, have been shown repeatedly.…”

mentioning

confidence: 99%

Hepatic adiponectin receptors (ADIPOR) 1 and 2 mRNA and their relation to insulin resistance in obese humans

et al. 2010

View full text Add to dashboard Cite

Objective: Adiponectin signalling attenuates insulin resistance (IR) and steatosis hepatis in animal models. As adiponectin receptor (ADIPOR)1 and ADIPOR2 are critical components in the adiponectin signalling cascade, we studied hepatic ADIPOR1/2 mRNA levels in humans and their relation to IR. Design: We determined metabolic risk factors and levels of hepatic mRNA transcribed from ADIPOR1, ADIPOR2 and FOXO1, a putative up-stream regulator, in 43 and 34 obese subjects with low and high homeostasis model assessment-IR, respectively. Results: Plasma adiponectin and metabolic risk factors showed associations with IR as expected. Both hepatic ADIPOR1 and ADIPOR2 mRNA expression levels were higher in insulin-resistant subjects (Po0.0035). ADIPOR1 mRNA correlated with FOXO1 mRNA in obese insulin resistant (P ¼ 0.0034), but not insulin-sensitive subjects, while no correlations of ADIPOR2 with FOXO1 mRNA were noted. FOXO1 enhanced transcription from the ADIPOR1, but not the ADIPOR2 promoter in HepG2 cells. Conclusion: Increased hepatic ADIPOR1 and ADIPOR2 mRNA in insulin-resistant obese subjects may, at least in part, reflect a compensatory mechanism for reduced plasma adiponectin. FOXO1 may contribute to enhanced ADIPOR1, but not ADIPOR2 transcription in IR.

show abstract

“…Wildman and his colleagues in their study have reported that 51.3% of overweight and 31.7% of obese adults were MHO [9]. Others have reported a prevalence from 6% to 40% in different overweight and obese populations [11,20,22,23]. Data available from a limited number of studies from the West shows the prevalence of MHO ranging from 11-40% whereas the prevalence of MONW is about 5-45% [24].…”

Section: Prevalencementioning

confidence: 94%

“…It also limits the infiltration of monocytes/ macrophages into adipose tissue and their conversion into foam cells in the vessel wall providing the anti-inflammatory and antiatherogenic effects. Additionally, adiponectin also increases insulin sensitivity, fatty acid oxidation and decreases secretion of glucose from liver, increases glucose uptake, and adipogenesis [22,33,36]. Adiponectin also promotes glucose metabolism and accelerates the oxidation of free fatty acids in the muscle [37,38].…”

Section: Adiponectinmentioning

confidence: 99%